What question did this study set out to answer?

To compare the efficacy and safety of dose-adjusted EPOCH-R against standard R-CHOP as frontline treatment for diffuse large B-cell lymphoma.

April 2, 2019Journal of Clinical Oncology

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

View Full Paper

Ask AI

Bookmark

Authors

NBNancy L. BartlettBoston University WWWyndham H. WilsonUniversity of Maryland, Baltimore SJSin‐Ho JungDuke University

Discussion

Member takes

Implication

Randomized phase III trial shows DA-EPOCH-R does not improve survival and adds toxicity over R-CHOP in diffuse large B-cell lymphoma, suggesting standard R-CHOP remains the preferred frontline...

Key Points

To compare the efficacy and safety of dose-adjusted EPOCH-R against standard R-CHOP as frontline treatment for diffuse large B-cell lymphoma.
Intergroup, phase III randomized trial (Alliance/CALGB 50303, NCT00118209).
Patients received six cycles of either DA-EPOCH-R or standard R-CHOP.
Primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), response rate, and safety.
DA-EPOCH-R did not improve progression-free survival or overall survival compared with standard R-CHOP.
The infusional DA-EPOCH-R regimen demonstrated increased toxicity relative to R-CHOP.
Treatment-related deaths occurred in 2.1% of patients (5 deaths) in each treatment arm.

Cite This Study

Bartlett et al. (2019) studied this question.

synapsesocial.com/papers/69f58e25489100c342afc02e https://doi.org/10.1200/jco.18.01994

View Full Paper

Ask AI

Bookmark

Implication

Randomized phase III trial shows DA-EPOCH-R does not improve survival and adds toxicity over R-CHOP in diffuse large B-cell lymphoma, suggesting standard R-CHOP remains the preferred frontline...

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Discussion

Member takes

Implication

Key Points

Cite This Study

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider